Loading company…
Precede Biosciences develops a liquid biopsy platform for precision medicine research.
Precede Biosciences analyzes circulating chromatin and DNA methylomes from 1 mL of plasma to provide insights into gene and pathway activity. Its platform serves researchers and physicians. Founded in 2021, the company is based in Massachusetts, US. It raised USD 63.5 million in Series B funding in January 2026 as part of a larger USD 83.5 million Series B and debt round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in